200 related articles for article (PubMed ID: 19754360)
1. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.
Reikvam H; Ersvaer E; Bruserud O
Curr Cancer Drug Targets; 2009 Sep; 9(6):761-76. PubMed ID: 19754360
[TBL] [Abstract][Full Text] [Related]
2. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
Reikvam H; Nepstad I; Sulen A; Gjertsen BT; Hatfield KJ; Bruserud Ø
Expert Opin Investig Drugs; 2013 May; 22(5):551-63. PubMed ID: 23586877
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors.
Abdalla AN; Abdallah ME; Aslam A; Bader A; Vassallo A; Tommasi N; Malki WH; Gouda AM; Mukhtar MH; El-Readi MZ; Alkahtani HM; Abdel-Aziz AA; El-Azab AS
Molecules; 2020 May; 25(9):. PubMed ID: 32397330
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?
Reikvam H; Brenner AK; Nepstad I; Sulen A; Bruserud Ø
Expert Opin Ther Targets; 2014 Aug; 18(8):929-44. PubMed ID: 24956934
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
6. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Reikvam H; Hatfield KJ; Ersvaer E; Hovland R; Skavland J; Gjertsen BT; Petersen K; Bruserud O
Br J Haematol; 2012 Feb; 156(4):468-80. PubMed ID: 22150087
[TBL] [Abstract][Full Text] [Related]
7. Targeting HSP90 for cancer therapy.
Mahalingam D; Swords R; Carew JS; Nawrocki ST; Bhalla K; Giles FJ
Br J Cancer; 2009 May; 100(10):1523-9. PubMed ID: 19401686
[TBL] [Abstract][Full Text] [Related]
8. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
10. Targeting Hsp90 in urothelial carcinoma.
Chehab M; Caza T; Skotnicki K; Landas S; Bratslavsky G; Mollapour M; Bourboulia D
Oncotarget; 2015 Apr; 6(11):8454-73. PubMed ID: 25909217
[TBL] [Abstract][Full Text] [Related]
11. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia--targeting of disease heterogeneity through direct and indirect antileukemic effects.
Bruserud Ø; Hatfield KJ; Reikvam H
Leuk Res; 2011 Sep; 35(9):1156-8. PubMed ID: 21802728
[No Abstract] [Full Text] [Related]
13. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
Erlichman C
Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
[TBL] [Abstract][Full Text] [Related]
14. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 Inhibition Reduces TLR5 Surface Expression and NF-
Na BH; Hoang TX; Kim JY
Biomed Res Int; 2018; 2018():4319369. PubMed ID: 29651431
[TBL] [Abstract][Full Text] [Related]
16. Heat shock proteins and acute leukemias.
Thomas X; Campos L; Le QH; Guyotat D
Hematology; 2005 Jun; 10(3):225-35. PubMed ID: 16019471
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.
Fredly H; Ersvær E; Gjertsen BT; Bruserud O
Oncol Rep; 2011 Jun; 25(6):1549-56. PubMed ID: 21431284
[TBL] [Abstract][Full Text] [Related]
18. The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.
Lazenby M; Hills R; Burnett AK; Zabkiewicz J
Leuk Res; 2015 Jun; 39(6):617-24. PubMed ID: 25882550
[TBL] [Abstract][Full Text] [Related]
19. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
20. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update.
Neckers L; Neckers K
Expert Opin Emerg Drugs; 2005 Feb; 10(1):137-49. PubMed ID: 15757409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
